Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Availability of written Informed Consent to participate in the study from the subject.~2. Male or female between 18 and 45 years old without previous contact with hepatitis B virus (HBV).~3. Good health condition based on full physical examination.~4. Normal values of laboratory biochemical blood tests.~5. Seronegative with respect to anti-HBs (surface) antibodies, anti-HBc (core) antibodies, and HBs Antigen (HBsAg) on screening.~6. Not pregnant and not breast-feeding.~7. For men and women of reproductive age: consent for use of an effective contraception method, for example, an intrauterine device, oral contraceptive, hypodermic implant or double barrier method (a condom with contraceptive sponge or contraceptive suppository) throughout the entire study.~Exclusion Criteria:~1. Congenital or inherited immunodeficiency disorder in family history.~2. Information of a serious blood disorder, cardiac disorder, or tumour.~3. Current use of any medication that could alter immune reactivity.~4. Infection with HBV at the present time or in the past, confirmed by HBV markers test.~5. Anaphylaxis or severe allergy, or atopy, history of alcoholism or drug abuse.~6. Pregnancy and breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sci-B-Vac® (Type: EXPERIMENTAL): The 3-antigen HepB vaccine, Sci-B-Vac® contains three recombinant proteins of HBV viral envelope: small S, medium pre-S2, and large pre-S1 surface antigens. Sci-B-Vac® was supplied in 1.0 ml vials.
- Engerix-B® (Type: ACTIVE_COMPARATOR): The single-antigen HepB vaccine, Engerix-B® (GSK), contains the small S recombinant protein. Engerix-B® was supplied in 1.0 ml vials.

Based on this trial design, predict the completion outcome and termination type (if applicable).